"Pakistan Pharmaceuticals & Healthcare Report Q3 2015" now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Sun May 10 2015

Medicine sales in Pakistan will continue to grow significantly from a low base. Underpinning this trajectory includes a reform in the country's pricing environment that will see scope for an increase in pharmaceutical prices. This will in turn encourage more investment from drugmakers to capture the commercial opportunities stemming from the country's epidemiological profile. Downside risks remain due to the lack of policy continuity and potential cost containment measures

Headline Expenditure Projections

* Pharmaceuticals: PKR231.2bn (USD2.29bn) in 2014 to PRK254.0bn (USD2.47bn) 2015; +9.8%in local currency terms and +7.7% in US dollar terms.
* Healthcare: PKR684.5bn (USD6.78bn) in 2014 to PKR758.0bn (USD7.36n) in 2015; +10.7% in local currency terms and +8.6% in US dollar terms.

Risk/Reward Index: Pakistan's Pharmaceutical Risk/Reward Index score for Q315 is 40.5 out of 100. This places it in the 16th out of 19 other markets in the Asia Pacific region. This low score is driven by the below-average Industry Rewards score, with a low market expenditure in USD dollar terms (scoring 10.0 out of 20.0), a low spending per capita in USD (scoring 1.2 out of 12) as well modest sector value growth (7.2 out of 12.0). Similarly the country's instability also drags down the Country's Risk score (13.0 out of 35).

Full Report Details at
- http://www.fastmr.com/prod/991621_pakistan_pharmaceuticals.aspx?afid=301

Key Trends & Developments

* In March 2015, children's vaccines for various diseases worth USD3.7mn donated by UNICEF have gone to waste due to the negligence to store them adequately. Frequent power outages were cited as a major reason for the damage, according to an official of the health ministry.
* Drugmakers in Pakistan raised concerns in February 2015 over claims that there are only 14 inspectors available in the Drug Regulatory Authority of Pakistan to examine the quality of an estimated 80,000 drugs manufactured by over 600 companies. According to the former chairman of the Pakistan Pharmaceutical Manufacturers Association Amjad Ali Jawa,...

The Pakistan Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Pakistan Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Pakistan pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Pakistan, to test other views - a key input for successful budgeting and strategic business planning in the Pakistani pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q3 2015
- Argentina Pharmaceuticals & Healthcare Report Q3 2015
- Central America Pharmaceuticals & Healthcare Report Q3 2015
- Thailand Pharmaceuticals & Healthcare Report Q3 2015
- Nigeria Pharmaceuticals & Healthcare Report Q3 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »